Loading
A phase 2 trial of Resminostat in Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas, run by 4SC AG, completed.
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) is a phase 2 interventional study registered as NCT02953301 by 4SC AG, with 201 participants recorded, started 2016-11 and reaching its primary completion in 2023-03. Interventions recorded: resminostat, Placebo. Conditions recorded: Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous.
Linked to the drug Resminostat because the registry names it among its interventions and Cutaneous T-cell lymphoma and Peripheral T-cell lymphomas among its conditions. Registry record only: no result has been read by an editor.
Shares 4SC, Resminostat and the tag pipeline.
Shares 4SC, Resminostat and the tag pipeline.
Shares Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.